Couverture de MD Newsline Metabolic Brief

MD Newsline Metabolic Brief

MD Newsline Metabolic Brief

De : MD Newsline
Écouter gratuitement

Offres de saison | 0,99 € par mois pendant les 3 premiers mois

5,99 €/mois par la suite. Des conditions s’appliquent. Annulation mensuelle possible.
Welcome to MD Newsline Metabolic Brief, your go-to source for concise, expert-led updates in endocrinology and metabolic health. Designed for busy healthcare professionals, this podcast delivers focused insights from leading endocrinologists, obesity specialists, and clinical experts. Each episode highlights the latest research, treatment strategies, and clinical developments in metabolic care, including obesity management, diabetes, thyroid disorders, and other endocrine conditions. From emerging therapies and clinical trial updates to real-world patient care approaches, we break down complex topics into clear, actionable takeaways. Whether you're an endocrinologist, physician, or part of the broader medical community, Metabolic Brief helps you stay informed with clear and focused insights. Our mission is to provide timely, relevant knowledge that supports better clinical decisions and improved patient outcomes. Tune in for quick, impactful insights shaping the future of metabolic and endocrine care.2026 Hygiène et vie saine Maladie et pathologies physiques
Épisodes
  • Chronic Obesity Care: GLP-1s and Bariatric Surgery ft. Dr. Christine Ren-Fielding

    Chronic Obesity Care: GLP-1s and Bariatric Surgery ft. Dr. Christine Ren-Fielding
    Oct 20 2026
    In this episode of MD Newsline, Dr. Christine Ren-Fielding, Professor of Surgery at NYU Langone Health and Director of the NYU Weight Management Center, discusses the evolving, multimodal landscape of chronic obesity treatment. Drawing on over 25 years of clinical experience, Dr. Ren-Fielding contrasts the traditional perception of obesity as a personal failure with its reality as a lifelong, progressive metabolic condition. She explores how the body's physiological set point defends against weight loss, compares obesity management to chronic disease models such as cancer care, and outlines how surgical procedures, GLP-1 receptor agonists, and psychiatric support intersect to optimize long-term health outcomes and limb/metabolic preservation. Episode Highlights The Multidisciplinary Approach to Obesity Dr. Ren-Fielding outlines the parallel structure of medical and surgical care at the NYU Weight Management Center. She detail how board-certified obesity medicine physicians, bariatric surgeons, nurse practitioners, dietitians, and psychologists collaborate seamlessly to provide continuous care tailored to individual patient trajectories. Obesity as a Chronic Condition and Set Point Adaptation The discussion delves into metabolic adaptation and set point theory, explaining how human physiology actively defends against calorie restriction. Dr. Ren-Fielding highlights an anecdotal 75-pound weight-gain threshold where conservative measures like diet and exercise face biological resistance, drawing an analogy to cancer remission where multi-step interventions—such as surgery, chemotherapy, or pharmacotherapy—are needed over a patient's lifespan. Limitations of BMI and Population-Specific Guidelines Dr. Ren-Fielding evaluates body mass index (BMI) as a diagnostic tool, pointing out its inability to distinguish muscle mass in athletes or account for visceral fat distribution. She highlights how lower BMI cutoffs are critical for Asian populations due to heightened risk for metabolic syndrome, type 2 diabetes, hypertension, and metabolic dysfunction-associated steatohepatitis (MASH) at lower body weights. Red Flag Comorbidities for PCP Referral The episode outlines key medical indicators that primary care physicians (PCPs) should evaluate alongside BMI, including metabolic syndrome, severe sleep apnea, coronary artery disease, and fatty liver disease (MASH)—a leading cause of liver transplantation. Dr. Ren-Fielding advocates for earlier surgical referral in high-risk patients to prevent long-term organ damage. Integrating GLP-1 Receptor Agonists with Surgical Interventions Dr. Ren-Fielding shares her long-term experience with GLP-1 receptor agonists (including liraglutide, semaglutide, and tirzepatide), from early clinical trials treating weight recurrence after gastric bypass to current preventative and combination therapy uses. She addresses pre-surgical optimization, the impact of menopause and hysterectomy on weight gain, and how GLP-1s serve as a non-surgical step for post-operative plateaus. Evaluating Bariatric Options: Sleeve Gastrectomy, Gastric Bypass, and Lap-Band The conversation explores clinical selection criteria for procedures like sleeve gastrectomy, Roux-en-Y gastric bypass, and adjustable gastric banding (Lap-Band). Key factors include patient compliance, hiatal hernia presence, gastroesophageal reflux disease (GERD), pregnancy timelines, and patient preference. Dr. Ren-Fielding also discusses the ethical considerations surrounding aggressive intestinal bypasses like the duodenal switch and SADI-S due to severe risk of chronic protein deficiency and vitamin deficiencies. Defining Clinical Success Beyond the Scale Dr. Ren-Fielding redefines successful bariatric and medical outcomes, emphasizing that modest, sustained weight loss improves cardiovascular health, glycemic control, fertility, and overall quality of life far more effectively than volatile, extreme weight loss followed by recurrence. Key Takeaway Managing chronic obesity requires a long-term, multimodal strategy that moves beyond simplistic caloric models. By integrating advanced bariatric surgery, targeted GLP-1 receptor agonist therapies, behavioral healthcare, and personalized clinical decision-making, care teams can achieve sustainable remission, manage metabolic comorbidities, and dramatically improve patient quality of life. RESOURCES Website — https://mdnewsline.com/ Newsletter — https://mdnewsline.com/subscribe/ Dr. Christine Ren Fielding — https://nyulangone.org/doctors/1083626359/christine-ren-fielding LinkedIn — https://www.linkedin.com/in/christine-ren-fielding-md-facs-29472a12
    Afficher plus Afficher moins
    50 min
  • Healing Diabetic Wounds with Vasculogenic Fibroblasts

    Healing Diabetic Wounds with Vasculogenic Fibroblasts
    Oct 13 2026

    In this episode of MD Newsline, Dr. Kanhaiya Singh, Associate Professor at the University of Pittsburgh and researcher specializing in diabetic foot ulcers and ischemic wound healing, discusses groundbreaking discoveries in regenerative medicine that could reshape the treatment of chronic diabetic wounds. Dr. Singh explains how a newly identified population of vasculogenic fibroblasts supports blood vessel formation during wound healing and how diabetes disrupts this natural repair mechanism through epigenetic changes involving microRNA-200B (MIR-200B).

    He also explores the promise of tissue nanotransfection (TNT) technology, an innovative gene delivery platform designed to locally reprogram cells and restore healthy wound healing without traditional cell therapy. The conversation covers the science behind fibroblast state changes, AI-assisted biomarker discovery, and the path toward translating these findings into future clinical treatments for diabetic limb ischemia and chronic foot ulcers.

    Episode Highlights Understanding Vasculogenic Fibroblasts

    Dr. Singh introduces the discovery of vasculogenic fibroblasts, a specialized subset of fibroblasts that acquire blood vessel-forming properties while retaining their original fibroblast identity. Unlike traditional cell fate conversion, these cells undergo a state change, enabling them to support vascular repair without losing their normal wound-healing functions.

    Diabetes, Epigenetics, and Impaired Wound Healing

    The discussion explores how chronic hyperglycemia alters the wound microenvironment through DNA hypermethylation and epigenetic regulation. These changes suppress the formation of vasculogenic fibroblasts, reducing vascular regeneration and increasing the likelihood of chronic wounds and recurrent diabetic foot ulcers.

    The Role of MIR-200B

    Dr. Singh explains why microRNA-200B (MIR-200B) has emerged as a key molecular regulator of wound healing. Elevated MIR-200B levels in diabetes inhibit the development of vasculogenic fibroblasts, while targeted inhibition restores blood vessel formation, improves tissue perfusion, and accelerates wound healing in preclinical models.

    Tissue Nanotransfection: A New Regenerative Therapy

    The episode highlights tissue nanotransfection (TNT), an innovative silicon chip technology developed to deliver genetic therapies directly through the skin. By locally delivering anti-MIR-200B molecules, TNT reprograms resident fibroblasts to enhance vascular regeneration without the need for stem cell transplantation or donor cells.

    Why Cell Therapy Has Fallen Short

    Dr. Singh discusses the limitations of traditional cell therapies for diabetic limb ischemia, including poor cell survival, immune challenges, and unfavorable wound environments. He explains why in vivo cellular reprogramming through TNT may provide a more effective and clinically practical alternative.

    Biomarkers, Artificial Intelligence, and Precision Wound Care

    The conversation explores how single-cell RNA sequencing, spatial transcriptomics, and artificial intelligence are advancing the search for predictive biomarkers. Dr. Singh describes ongoing efforts within the Diabetic Foot Consortium to develop AI-driven tools capable of predicting whether diabetic wounds are likely to heal or become chronic.

    Translating Research into Clinical Practice

    Dr. Singh outlines the remaining steps before this technology reaches patients, including FDA approval of the tissue nanotransfection platform and clinical development of antisense oligonucleotide therapies. He anticipates that early clinical translation could begin within the next several years.

    Key Takeaway

    Dr. Singh emphasizes that improving diabetic wound healing requires more than simply closing wounds—it requires restoring healthy vascular biology. By combining epigenetics, regenerative medicine, tissue nanotransfection, and artificial intelligence, researchers are moving toward personalized therapies capable of preventing chronic wounds, improving limb preservation, and reducing diabetic complications.

    Resources

    Website: https://mdnewsline.com/

    Newsletter: https://mdnewsline.com/subscribe/

    Contact with Dr. Kanhaiya Singh: Here
    Afficher plus Afficher moins
    20 min
  • Beyond Autoantibodies: A New Approach to Predicting Type 1 Diabetes in Children

    Beyond Autoantibodies: A New Approach to Predicting Type 1 Diabetes in Children
    Sep 29 2026
    In this episode of MD Newsline, Dr. Brittany Bruggeman, a pediatric endocrinologist and physician-scientist at the University of Florida, discusses groundbreaking research presented at the American Diabetes Association (ADA) Scientific Sessions on the role of the exocrine pancreas in predicting Type 1 diabetes. Traditionally, researchers have focused on the insulin-producing islets, but Dr. Bruggemann explains why the much larger exocrine pancreas may hold valuable clues for identifying children at the highest risk of developing Type 1 diabetes years before symptoms appear. She explores findings from the TEDDY birth cohort, showing that changes in fecal elastase, a marker of exocrine pancreatic function, can be detected as early as four months of age in children who later develop Stage 3 Type 1 diabetes. Dr. Bruggemann also discusses how combining exocrine biomarkers with islet autoantibodies improves prediction accuracy, the clinical implications of exocrine pancreatic insufficiency, and how future advances in proteomics, imaging, AI, and multiomics may transform early diagnosis and disease prevention. Episode Highlights Why the Exocrine Pancreas Matters For decades, Type 1 diabetes research has centered on the insulin-producing islets. Dr. Bruggemann explains why researchers are now shifting attention to the exocrine pancreas, which makes up approximately 97% of the pancreas and may show measurable changes long before clinical diabetes develops. The TEDDY Study and Early Biomarkers Using more than 4,500 stool samples collected from over 250 children enrolled in the TEDDY study, researchers measured fecal elastase, a marker of exocrine pancreatic function, to determine whether early pancreatic changes could predict progression to Type 1 diabetes. Detecting Changes Before Autoimmunity One of the study's most surprising findings was that children who progressed rapidly to Stage 3 Type 1 diabetes already demonstrated differences in fecal elastase at an average age of four months—well before islet autoimmunity is thought to begin. This suggests that exocrine abnormalities may precede the autoimmune process itself. Improving Prediction by Combining Biomarkers Fecal elastase alone provided limited predictive power, but when combined with islet autoantibody status, researchers significantly improved their ability to predict progression to Stage 3 Type 1 diabetes within a one- to two-year timeframe—an important goal for clinical trials and disease-modifying therapies. Clinical Implications for Patients Dr. Bruggemann explains when clinicians should consider testing for exocrine pancreatic insufficiency, particularly in patients with established Type 1 diabetes who experience gastrointestinal symptoms such as bloating, cramping, or stool changes. She emphasizes that fecal elastase testing is inexpensive, reliable, and can identify a treatable condition that is often overlooked. Challenges and Limitations Although promising, fecal elastase testing requires stool collection, and sample quality can influence results. Dr. Bruggemann discusses current limitations and ongoing efforts to develop symptom-based screening tools that could help identify which patients should undergo testing. The Future of Type 1 Diabetes Prediction Looking ahead, Dr. Bruggemann envisions combining fecal elastase, serum biomarkers, genetic data, MRI imaging, proteomics, and artificial intelligence to build more accurate risk prediction models capable of identifying children most likely to develop Type 1 diabetes within the next few years. Key Takeaway Dr. Bruggemann's research suggests that the exocrine pancreas may provide previously overlooked biomarkers that improve the early prediction of Type 1 diabetes. While fecal elastase is not sufficient as a standalone predictor, combining it with autoantibodies, serum biomarkers, genetics, and advanced imaging could lead to earlier intervention, better clinical trial enrollment, and a deeper understanding of how Type 1 diabetes begins long before symptoms appear. Resources Website: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/ Contact with Dr. Brittany Bruggeman: Here
    Afficher plus Afficher moins
    20 min
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment